Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

BACKGROUND: The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We investigated the efficacy of T or L with neoadjuvant che...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Alba, E, Albanell, J, de la Haba, J, Barnadas, A, Calvo, L, Sánchez-Rovira, P, Ramos, M, Rojo, F, Burgués, O, Carrasco, E, Caballero, R, Porras, I, Tibau, A, Cámara, M C, Lluch, A
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2014
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3950860/
https://ncbi.nlm.nih.gov/pubmed/24457911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.831
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller